JP2000510107A - ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法 - Google Patents

ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法

Info

Publication number
JP2000510107A
JP2000510107A JP09538394A JP53839497A JP2000510107A JP 2000510107 A JP2000510107 A JP 2000510107A JP 09538394 A JP09538394 A JP 09538394A JP 53839497 A JP53839497 A JP 53839497A JP 2000510107 A JP2000510107 A JP 2000510107A
Authority
JP
Japan
Prior art keywords
ligand
biological material
pathogen
receptor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP09538394A
Other languages
English (en)
Japanese (ja)
Inventor
バレット，ノエル
アイブル，ヨハン
ドルナー，フリードリッヒ
ペルスラー，ゲルハルト
ヘンマーレ，トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Publication of JP2000510107A publication Critical patent/JP2000510107A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP09538394A 1996-04-30 1997-04-23 ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法 Pending JP2000510107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0078096A AT403477B (de) 1996-04-30 1996-04-30 Biologisches material frei von viralen und molekularen pathogenen und verfahren zur herstellung
AT780/96 1996-04-30
PCT/AT1997/000075 WO1997040861A1 (de) 1996-04-30 1997-04-23 Biologisches material frei von viralen und molekularen pathogenen und verfahren zur herstellung

Publications (1)

Publication Number Publication Date
JP2000510107A true JP2000510107A (ja) 2000-08-08

Family

ID=3499569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09538394A Pending JP2000510107A (ja) 1996-04-30 1997-04-23 ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法

Country Status (8)

Country Link
EP (1) EP0900089A1 (de)
JP (1) JP2000510107A (de)
AT (1) AT403477B (de)
AU (1) AU731048B2 (de)
CA (1) CA2253300A1 (de)
IL (1) IL126810A0 (de)
NO (1) NO984979L (de)
WO (1) WO1997040861A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US6620629B1 (en) 1997-02-21 2003-09-16 The Regents Of The University Of California Method for detecting prions
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
AU726999B2 (en) * 1997-06-13 2000-11-30 Baxter Aktiengesellschaft Process for reducing the concentration of viral and molecular pathogens in a biological material
DE19752898A1 (de) * 1997-11-28 1999-08-05 Centeon Pharma Gmbh Verfahren zum Nachweis hoher Vierenkonzentrationen im Blutplasma und/oder Blutserum mittels der Polymerasekettenreaktion
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
ATE318176T1 (de) * 1998-08-31 2006-03-15 Julian L Ambrus Verfahren zur entfernung von hiv und anderen viren aus blut
AU4309201A (en) * 1999-12-02 2001-06-12 V.I. Technologies, Inc. Method of identifying a ligand for a target molecule
WO2002062956A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Chemomagnetic retrieval of cmv and cmv infected cells
WO2004064608A2 (en) 2003-01-17 2004-08-05 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896218A (en) * 1972-07-13 1975-07-22 Research Corp Radiommunoassay determining the hepatitis associated antigen content of blood
CA1207662A (en) * 1982-12-02 1986-07-15 Ricardo H. Landaburu Hepatitis b and non-a-non-b-safe biological products
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
DE69016656T2 (de) * 1989-06-15 1995-05-24 Smith Jun Vorrichtung zur inaktivierung infektioeser erreger und zur verhinderung der koagulierung in biologischen flüssigkeiten.
ATE177781T1 (de) * 1990-02-20 1999-04-15 Baxter Int Gereinigtes, virusfreies menschliches thrombin
EP0447984A1 (de) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmunglobulin gegen Hepatitis-C-Virus und Verfahren zur Herstellung
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
EP0679405A1 (de) * 1994-04-25 1995-11-02 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Abtrennung von Viren aus Proteinlösungen
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate

Also Published As

Publication number Publication date
CA2253300A1 (en) 1997-11-06
IL126810A0 (en) 1999-08-17
NO984979L (no) 1998-12-23
WO1997040861A1 (de) 1997-11-06
AU731048B2 (en) 2001-03-22
AU2561297A (en) 1997-11-19
AT403477B (de) 1998-02-25
ATA78096A (de) 1997-07-15
NO984979D0 (no) 1998-10-26
EP0900089A1 (de) 1999-03-10

Similar Documents

Publication Publication Date Title
Burnouf et al. Nanofiltration of plasma‐derived biopharmaceutical products
JP4031833B2 (ja) プリオンのクロマトグラフィー除去方法
ES2295308T3 (es) Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
JP2008500959A (ja) ウイルスについて安全な免疫グロブリンの製造方法
Yokoyama et al. Removal of small non‐enveloped viruses by nanofiltration
US20100129893A1 (en) Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin
JP2000510107A (ja) ウイルス性及び分子性病原体不含の生物学的材料及びその製造方法
Bos et al. Virus validation of pH 4-treated human immunoglobulin produced by the Cohn fractionation process
US6391657B1 (en) Removal of viruses from protein solutions by ultrafiltration
CA1066191A (en) Hepatitis b vaccine
US6407212B1 (en) Method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions
Van Holten et al. Incorporation of an additional viral‐clearance step into a human immunoglobulin manufacturing process
Koenderman et al. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step
Caballero et al. Viral safety characteristics of Flebogamma® DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin
Morgenthaler Securing viral safety for plasma derivatives
CN101306200A (zh) 静脉注射用乙型肝炎人免疫球蛋白的制备方法
JP2002505674A (ja) 生物材料中のウイルスおよび分子病原体を除去する方法
RU2728724C2 (ru) Способ получения вирусбезопасного раствора иммуноглобулина g человека для внутримышечного введения
Alarifi Nanofiltration for blood products
Burnouf et al. Strategy of virus removal/inactivation of plasma-derived products: Interest of nanofiltration as a new virus elimination method
Poelsler et al. Validation of adventitious agent safety in Yimmugo®, a novel IVIG preparation for human use
Foster Plasma fractionation
JP2000319294A (ja) 生物由来高分子溶液精製方法
Foster et al. 20 FRACTIONATED PRODUCTS
Aranha-Creado Ensuring Virological Safety of Biologicals: Virus Removal from Biological Fluids by Filtration